ERBB2 mRNA as predictor of response to anti-HER2 antibody-drug conjugates (ADC) in breast cancer (BC)

被引：0
|
作者：
Griguolo, G. [1 ]
Braso-Maristany, F. [2 ]
Pascual, T. [3 ]
Chic, N. [4 ]
Vidal, M. [4 ]
Adamo, B. [4 ]
Giarratano, T. [1 ]
Dieci, M. V. [5 ]
Guarneri, V. [5 ]
Prat, A. [2 ]
机构：
[1] Ist Oncol Veneto IRCCS, Med Oncol 2, Padua, Italy
[2] Inst Invest Biomed August Pi & Sunyer IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain
[3] SOLTI Breast Canc Cooperat Grp, Barcelona, Spain
[4] Hosp Clin Barcelona, Med Oncol, Barcelona, Spain
[5] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
20P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Differential Signaling by ErbB Receptor (HER) Dimers: Implications for Response to Anti-HER2 Therapies in Breast Cancer
    Ghosh, R.
    Narasanna, A.
    Gonazalez-Angulo, A. M.
    Mills, G.
    Arteaga, C. L.
    CANCER RESEARCH, 2009, 69 (24) : 525S - 525S
  • [32] Antibody-Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
    Mcnamara, Blair
    Greenman, Michelle
    Pebley, Nicole
    Mutlu, Levent
    Santin, Alessandro D.
    MOLECULES, 2023, 28 (21):
  • [33] Homogeneous antibody-drug conjugates: DAR 2 anti-HER2 obtained by conjugation on isolated light chain followed by mAb assembly
    Farras, Merce
    Miret, Joan
    Camps, Marc
    Roman, Ramon
    Martinez, Oscar
    Pujol, Xavier
    Erb, Stephane
    Ehkirch, Anthony
    Cianferani, Sarah
    Casablancas, Antoni
    Cairo, Jordi Joan
    MABS, 2020, 12 (01)
  • [34] BAT8001, a potent anti-HER2 antibody-drug conjugate with a novel stable linker for the treatment of HER2-positive breast cancer
    Tang, W.
    Deng, X.
    Ou, Z.
    Gan, J.
    Dong, Q.
    Tan, B.
    Lu, L.
    Chen, B.
    Bao, C.
    Li, S.
    Thomas, B.
    Yu, J-C
    CANCER RESEARCH, 2019, 79 (04)
  • [35] ERBB2 (HER2) Testing in Breast Cancer
    Hilal, Talal
    Romond, Edward H.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (12): : 1280 - 1281
  • [36] Recent advances of antibody-drug conjugates in treating breast cancer with different HER2 status
    Qiu, Yue
    Shi, Yaqin
    Chao, Zhujun
    Zhu, Xinyu
    Chen, Yan
    Lu, Linlin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [37] HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies
    Gandullo-Sanchez, Lucia
    Capone, Emily
    Ocana, Alberto
    Iacobelli, Stefano
    Sala, Gianluca
    Pandiella, Atanasio
    EMBO MOLECULAR MEDICINE, 2020, 12 (05)
  • [38] HER2-targeted antibody-drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia
    Rainone, Michael
    Behrendt, Carolyn E.
    Kasparian, Saro
    Nguyen, Tina
    Sedrak, Mina S.
    Lavasani, Sayeh
    Stewart, Daphne B.
    Yuan, Yuan
    Mortimer, Joanne E.
    Waisman, James R.
    Patel, Niki
    Pullarkat, Vinod
    BREAST CANCER, 2023, 30 (05) : 796 - 801
  • [39] Statin therapy enhances the efficacy of HER2 directed antibody-drug conjugates in breast cancer
    Liu, Bo
    Drago, Joshua Z.
    Rao, Yi
    Pereira, Patricia R.
    Safonov, Anton
    Marra, Antonio
    Ahmed, Mehnaj S.
    Modi, Shanu
    Reis-Filho, Jorge S.
    Montemurro, Filippo
    Razavi, Pedram
    Lewis, Jason S.
    Chandarlapaty, Sarat
    CANCER RESEARCH, 2022, 82 (12)
  • [40] Trastuzumab: Anti-HER2 antibody for treatment of metastatic breast cancer
    Wong, WM
    CANCER PRACTICE, 1999, 7 (01) : 48 - 50
12345